Stable Estrogen, Stable Bone Mass
Estrogen keeps bone formation and resorption in balance before menopause.
- ~30: Peak bone mass age (reached in early adulthood)
- ±0.3%: Baseline annual BMD change (slow balanced turnover)
- 100%: Estrogen (relative) (premenopausal reference level)
- ~200 d: Remodeling cycle length (resorption then formation)
Estrogen restrains osteoclasts
Estrogen suppresses RANKL and osteoclast lifespan directly.
Coupled remodeling
Formation and resorption stay tightly matched pre-menopause.
Bone mass is essentially flat for decades before menopause.
Peak bone mass matters
Higher peak mass delays reaching fracture-risk thresholds later.
Ovarian Output Starts to Waver
Estrogen swings and gradually falls in the years before menopause.
- 4–8 yrs: Typical perimenopause span (before final period)
- ~25%: Estrogen at onset (of premenopausal level)
- 0.3–1.8%: Annual BMD loss here (ramping upward)
- Rising: FSH trend (signals declining ovarian reserve)
Fluctuating, not linear
Estrogen swings unpredictably before its final decline.
Early bone signal
Bone turnover markers rise before periods even stop.
Window for screening
Baseline bone density scans are most useful here.
Loss often begins before menopause is even diagnosed.
Osteoclast Activity Surges
Losing estrogen releases osteoclasts from their normal restraint.
- ↑ sharply: RANKL/OPG ratio (favors osteoclast activation)
- ↑ 2–3×: Osteoclast lifespan (reduced apoptosis without estrogen)
- ~1.8–4.5%: Annual BMD loss (accelerating at onset)
- ~10–25%: Estrogen (relative) (post-ovarian-shutdown level)
RANKL unleashed
Estrogen loss raises RANKL signaling to osteoclast precursors.
Resorption outpaces formation
Osteoblasts cannot keep up with the new resorption rate.
This is the mechanistic switch behind post-menopausal bone loss.
Trabecular bone hit first
High-turnover spongy bone thins before dense cortical bone.
Years 1–5 Post-Menopause
Bone mass falls at its fastest rate in this early window.
- up to 4.5%: Peak annual loss (years 1–3 post-menopause)
- ~10–15%: 5-year cumulative loss (untreated trajectory)
- Spine faster: Spine vs hip loss (more trabecular bone)
- rising: Fracture risk multiplier (tracks cumulative loss)
The steepest years
Loss rate peaks then gradually tapers after year five.
Cumulative damage compounds
Each lost percent lowers the base for the next year.
Fracture risk climbs
Lower density sharply raises spine and hip fracture odds.
Untreated, this window accounts for most lifetime bone loss.
Dampening Resorption With Hormone Replacement
Restoring estrogen slows osteoclasts and stabilizes bone mass.
- up to 72%: HRT loss-rate reduction (at full modeled dose)
- +: BMD effect vs placebo (preserved density with HRT)
- ~30–40%: Fracture risk reduction (with sustained therapy)
- While on therapy: Effect persistence (benefit fades after stopping)
Estrogen replacement mechanism
HRT restores the RANKL-suppressing signal lost at menopause.
Dose-dependent effect
Higher HRT dose tracks with lower resorption rate.
Compare the treated lattice against the untreated ghost trajectory.
A branch point, not a cure
Timing and duration both shape the long-term outcome.